CN106323794B - Method for detecting process stability of gallbladder warming tablets - Google Patents
Method for detecting process stability of gallbladder warming tablets Download PDFInfo
- Publication number
- CN106323794B CN106323794B CN201510381434.5A CN201510381434A CN106323794B CN 106323794 B CN106323794 B CN 106323794B CN 201510381434 A CN201510381434 A CN 201510381434A CN 106323794 B CN106323794 B CN 106323794B
- Authority
- CN
- China
- Prior art keywords
- synephrine
- mobile phase
- tablet
- content
- gallbladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000010792 warming Methods 0.000 title claims description 47
- 210000000232 gallbladder Anatomy 0.000 title claims description 42
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 claims abstract description 189
- 229960003684 oxedrine Drugs 0.000 claims abstract description 94
- 238000012546 transfer Methods 0.000 claims abstract description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 69
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 30
- 244000183685 Citrus aurantium Species 0.000 claims description 24
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 24
- 238000001514 detection method Methods 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 241000675108 Citrus tangerina Species 0.000 claims description 13
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 10
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 9
- 239000005695 Ammonium acetate Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 229940043376 ammonium acetate Drugs 0.000 claims description 9
- 235000019257 ammonium acetate Nutrition 0.000 claims description 9
- 150000002009 diols Chemical class 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- 230000004580 weight loss Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- 241000207199 Citrus Species 0.000 claims description 4
- 235000020971 citrus fruits Nutrition 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 9
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 32
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 32
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 32
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 32
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 32
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 32
- 229940025878 hesperidin Drugs 0.000 description 32
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 32
- 239000000463 material Substances 0.000 description 19
- 239000010389 wendan Substances 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000012086 standard solution Substances 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 239000000341 volatile oil Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 8
- 244000197580 Poria cocos Species 0.000 description 7
- 235000008599 Poria cocos Nutrition 0.000 description 7
- 238000004811 liquid chromatography Methods 0.000 description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 description 6
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 6
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 6
- 235000011477 liquorice Nutrition 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 5
- 235000017491 Bambusa tulda Nutrition 0.000 description 5
- 241001330002 Bambuseae Species 0.000 description 5
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 5
- 239000011425 bamboo Substances 0.000 description 5
- 239000010135 fructus aurantii immaturus Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 244000164480 Curcuma aromatica Species 0.000 description 3
- 235000003398 Curcuma aromatica Nutrition 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 241000096270 Swertia leducii Species 0.000 description 3
- 241000244155 Taenia Species 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 238000010812 external standard method Methods 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 2
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 2
- 235000016646 Citrus taiwanica Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of pharmaceutical chemicals, and relates to a method for detecting the process stability of a lining tablet, which comprises the step of measuring the synephrine transfer rate of the lining tablet. The method can quickly and accurately detect whether the process stability of the temperature control liner sheets in each batch is qualified or not, thereby accurately stabilizing the product quality of the temperature control liner sheets.
Description
Technical Field
The invention belongs to the field of pharmaceutical chemicals, and relates to a method for detecting the process stability of a gallbladder warming tablet.
Background
The gallbladder warming tablet is a medicine developed in the traditional Chinese medicine pharmacy of the first subsidiary hospital of Guangzhou Chinese medicine university, which is approved as the No. 98 Hospital A-294 of the Tiaowei medical (province) in 1998 and can treat vertigo, emesis, vexation, insomnia, palpitation, epilepsy and other diseases.
The preparation method of WENDAN tablet comprises mixing radix Curcumae, rhizoma Pinelliae Preparata, fructus Aurantii Immaturus, pericarpium Citri Tangerinae, Glycyrrhrizae radix, caulis Bambusae in Taenia and Poria, sequentially extracting with solvent, concentrating, precipitating with ethanol and refining. Because the process steps of the lining warming tablet are multiple and the related components are complex, no method for detecting the quality stability or the process stability exists at present, and the quality or the process of the lining warming tablet cannot be controlled.
Synephrine is an adrenoceptor stimulant, has the effects of improving metabolism, increasing calorie consumption and oxidizing fat, is widely applied to the industries of medicine, food, beverage and the like, is named as 4- [ 1-hydroxy-2- (methylamino) ethyl ] phenol by IUPAC (IUPAC), and has the following structural formula:
disclosure of Invention
The traditional Chinese medicine preparation gallbladder warming tablet has various medicinal materials, complex components and complicated process links, and a method for detecting the process stability is not available at present. The inventor of the invention surprisingly finds that the process stability of the warming-in-container tablet can be detected by measuring the synephrine transfer rate of the warming-in-container tablet, thereby well controlling the product quality stability of the warming-in-container tablet.
The seven medicinal materials for producing the gallbladder warming tablet of the invention have the following proportions: 800 parts of bamboo shavings, 700 parts of rhizoma pinellinae praeparata, 700 parts of radix curcumae, 300 parts of liquorice, 100 parts of dried orange peel, 800 parts of poria cocos and 800 parts of immature bitter orange.
Specifically, 750 parts by weight of caulis bambusae in taeniam, 600 parts by weight of rhizoma pinellinae praeparata in 450-.
Preferably, 660 parts of caulis bambusae in taeniam, 550 parts of rhizoma pinellinae praeparata, 550 parts of radix curcumae, 165 parts of liquorice, 165 parts of dried orange peel, 550 parts of poria cocos and 660 parts of immature bitter orange. Or 500 parts of caulis bambusae in taeniam, 450 parts of rhizoma pinellinae praeparata, 500 parts of radix curcumae, 150 parts of liquorice, 200 parts of pericarpium citri reticulatae, 600 parts of poria cocos and 700 parts of immature bitter orange.
The preparation method of the gallbladder warming tablet comprises the following steps: mixing radix Curcumae, rhizoma Pinelliae Preparata, fructus Aurantii Immaturus, pericarpium Citri Tangerinae, Glycyrrhrizae radix, caulis Bambusae in Taenia and Poria at above ratio, soaking in water for half an hour, heating to boil, reflux-extracting for 1-2h, extracting twice, condensing during extraction to collect volatile oil, filtering the extractive solution, concentrating, precipitating with ethanol, filtering, concentrating the supernatant to obtain soft extract, adding adjuvants to make into granule, spraying volatile oil, and tabletting. The collected volatile oil contains the components of the raw medicinal materials and is also an effective component for exerting the drug effect.
The gallbladder warming tablet is produced by seven medicinal materials, wherein the content determination and the chemical component research of rhizoma pinellinae praeparata, radix curcumae, caulis bambusae in taeniam and poria cocos are not related in pharmacopoeia of the people's republic of china (2010 edition). Only the literature can be found that rhizoma Pinelliae Preparata contains trigonelline, radix Curcumae contains curcumin, and caulis Bambusae in Taenia contains tricin.
The inventor researches the three components and the raw medicinal materials and finds that: when the medicinal material curcuma aromatica is curcuma aromatica, the curcuma aromatica does not contain curcumin; the content of the tricin in the bamboo shavings is only 0.0087%, and the content is too low to be detected easily; in addition to rhizoma Pinelliae Preparata, radix Glycyrrhizae also contains trigonelline and has a content higher than that of rhizoma Pinelliae Preparata, and has poor specificity of trigonelline component, and radix Glycyrrhizae is a messenger drug, and its component is not suitable as index; accordingly, none of the above three components is suitable as a detection index.
The inventor carries out intensive research on two medicinal materials of the tangerine peel and the immature bitter orange, and finds that the tangerine peel and the immature bitter orange both contain hesperidin and synephrine, and the chemical components of the tangerine peel and the immature bitter orange are close. The inventor researches the quality stability and the process stability of the warming gallbladder tablets by taking hesperidin and synephrine as detection indexes respectively, and finds that the transfer rate of the hesperidin is too low in the process of preparing the warming gallbladder tablets, so that the detection is easy to cause inaccuracy and is not suitable for serving as the index, and the synephrine transfer rate is higher and is suitable for serving as the detection index.
The invention relates to a method for detecting the process stability of a lining warming tablet, which comprises the step of measuring the synephrine transfer rate of the lining warming tablet.
In one embodiment of the method of the invention, when the synephrine transfer rate is more than or equal to 40.8%, the process stability is qualified; specifically, the process stability is qualified when the synephrine transfer rate is more than or equal to 41%, more than or equal to 42%, more than or equal to 43.5%, more than or equal to 44%, more than or equal to 45.4%, more than or equal to 46%, more than or equal to 47%, more than or equal to 48%, more than or equal to 49%, more than or equal to 50%, or more than or equal to 50.21%.
In one embodiment of any of the methods of the invention, the synephrine transfer rate is 100% × synephrine mass in fel tablet (μ g)/synephrine mass in the drug (μ g).
In one embodiment of any of the methods of the invention, the amount of synephrine in the herbal material (μ g) is the amount of synephrine in the prescribed citrus aurantium (μ g) + the amount of synephrine in the prescribed citrus peel (μ g); specifically, the mass (μ g) of synephrine in the prescription fructus aurantii immaturus is equal to the mass (g) of the prescription fructus aurantii immaturus multiplied by the content (μ g/g) of synephrine in the prescription fructus aurantii immaturus; specifically, the mass (μ g) of synephrine in the prescribed pericarpium citri reticulatae is equal to the mass (g) of the prescribed pericarpium citri reticulatae multiplied by the content (μ g/g) of synephrine in the prescribed pericarpium citri reticulatae.
In one embodiment of any of the methods of the invention, the determination of synephrine content in the prescription citrus aurantium is made in accordance with pharmacopoeia of the people's republic of china (2010 version), p 230; specifically, the method for measuring the content of synephrine in the tangerine peel comprises the steps of mixing the tangerine peel and methanol, and measuring the content of the synephrine in an extracting solution by liquid chromatography.
In any embodiment of the methods of the invention, the determination of the synephrine content of citrus peel comprises any one or more of the following (1) to (4),
(1) before mixing, crushing the dried orange peel into medium powder;
(2) adding 50-100mL of methanol into per gram of dried orange peel;
(3) mixing under ultrasound; specifically, after ultrasonic treatment, methanol is used for complementing loss weight loss;
(4) filtering the extractive solution; specifically, the filter pore size is 0.22. mu.m.
In one embodiment of any of the methods of the present invention, the liquid chromatography detection conditions for measuring the content of citrus peel synephrine are any one or more of the following (1) to (7),
(1) the chromatographic column is a normal phase silica gel bonded diol-based chromatographic column;
(2) the detection wavelength is 275 nm;
(3) the flow rate of the mobile phase is 0.6-1.2 mL/min;
(4) the theoretical plate number is more than or equal to 14000;
(5) the liquid chromatography is high performance liquid chromatography;
(6) column temperature: 35 ℃;
(7) mobile phase a was a 5mM ammonium acetate solution, mobile phase B was acetonitrile, the mobile phase A, B volume percent changes are as follows,
in any embodiment of the method of the present invention, the quality measurement of synephrine in the Winterian tablets comprises the steps of mixing the Winterian tablets with methanol and measuring the content of synephrine in the extract by liquid chromatography.
In any of the embodiments of the methods of the invention, the Wencandine synephrine assay comprises any one or more of the following (1) to (5),
(1) before mixing, crushing the warm gall pieces;
(2) mixing under ultrasound; specifically, after ultrasonic treatment, methanol is used for complementing loss weight loss;
(3) the methanol concentration is 50-100% v/v;
(4) adding 50-100mL of methanol into each gram of gallbladder warming tablets;
(5) filtering the extractive solution; specifically, the filtrate is further purified; the preferred purification step is evaporation of the filtrate to dryness, dissolution of the residue and elution through a polyamide column.
In any embodiment of the method of the present invention, the conditions for the liquid chromatography detection of the content of the Chondrus crispus are any one or more of the following (1) to (6),
(1) the chromatographic column is a normal phase silica gel bonded diol-based chromatographic column;
(2) acetonitrile and ammonium acetate solution are used as mobile phases; preferably, acetonitrile is used as the mobile phase A, and 5mmol/L ammonium acetate solution is used as the mobile phase B; more preferably, the volume ratio of mobile phase a to mobile phase B is (60-95): (5-40);
(3) the detection wavelength is 275 nm;
(4) the flow rate of the mobile phase is 0.6-1.2 mL/min;
(5) the theoretical plate number is more than or equal to 14000;
(6) the liquid chromatography is high performance liquid chromatography.
In the present invention, the term "process stability" refers to the ability of the process to withstand fluctuations in materials and process and equipment changes without negative quality impact (ICH process robustness).
In the present invention, the term "medium powder" means powder which can pass through the sieve No. four in its entirety, but mixed with powder which can pass through the sieve No. five by not more than 60%.
In the present invention, the term "theoretical plate number" refers to one of column efficiency parameters of chromatography, and is used to quantitatively express the separation efficiency of a chromatography column.
Advantageous effects of the invention
(1) The stability of the gallbladder warming tablet process is detected by the synephrine transfer rate value of the gallbladder warming tablet.
(2) The invention further takes the synephrine transfer rate of the warming gallbladder tablets to be more than or equal to 40.8 percent as the qualified standard of the process stability of the warming gallbladder tablets, thereby realizing the control of the product quality of the warming gallbladder tablets.
(3) The liquid chromatography detection of the invention uses the normal phase silica gel bonded diol-based chromatographic column, which can better retain the synephrine component, and has the advantages of shorter equilibrium time, higher determination speed, higher sensitivity and higher separation degree.
In addition, the normal phase silica gel bonded diol-based chromatographic column does not need to be added with an ion pair reagent, so that the damage to the chromatographic column is reduced, and the synephrine component can be better kept on the chromatographic column.
(4) The sample extraction method is simple, the impurity content of the sample is low, the interference on a liquid chromatograph is reduced, and the detection accuracy is improved.
Drawings
FIG. 1: the invention adopts acetonitrile and 5mmol/L ammonium acetate solution with the volume ratio of 80:20 as mobile phase to detect the liquid chromatogram of the content of synephrine in the Windon tablet I.
FIG. 2: the invention adopts acetonitrile and 5mmol/L ammonium acetate solution with the volume ratio of 90:10 as mobile phase to detect the liquid chromatogram of the content of synephrine in the Windon tablet I.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products commercially available.
Preparation of Yiwendan tablets
Preparation example 1
Mixing 660 parts of seven medicinal materials including bamboo shavings, 550 parts of rhizoma pinellinae praeparata, 550 parts of radix curcumae, 165 parts of liquorice, 165 parts of dried orange peel, 550 parts of poria cocos and 660 parts of immature bitter orange in proportion, adding water to soak for half an hour, heating to boil, performing reflux extraction for 1.5 hours, extracting twice, condensing and collecting volatile oil in the extraction process, filtering the extracting solution, concentrating at 80 ℃, performing ethanol precipitation and filtration, concentrating the supernatant into thick paste at 80 ℃, adding dextrin to prepare granules, spraying the volatile oil, and tabletting to obtain the first batch of gallbladder warming tablets.
Preparation example 2
Mixing 550 parts by weight of seven medicinal materials of bamboo shavings, 450 parts by weight of rhizoma pinellinae praeparata, 450 parts by weight of radix curcumae, 150 parts by weight of liquorice, 150 parts by weight of dried orange peel, 450 parts by weight of poria cocos and 550 parts by weight of immature bitter orange in proportion, adding water for soaking for half an hour, heating to boil, performing reflux extraction for 1.5h, extracting twice, collecting volatile oil in the extraction process, filtering the extracting solution, concentrating at 80 ℃, performing ethanol precipitation and filtration, concentrating the supernatant into thick paste at 80 ℃, adding dextrin to prepare granules, spraying the volatile oil, and tabletting to obtain the second batch of the gallbladder warming tablets.
Preparation example 3
Mixing 750 parts by weight of seven medicinal materials of bamboo shavings, 600 parts by weight of rhizoma pinellinae praeparata, 600 parts by weight of radix curcumae, 250 parts by weight of liquorice, 250 parts by weight of dried orange peel, 600 parts by weight of poria cocos and 700 parts by weight of immature bitter orange in proportion, adding water for soaking for half an hour, heating to boil, performing reflux extraction for 1.5h, extracting twice, collecting volatile oil in the extraction process, filtering the extracting solution, concentrating at 80 ℃, performing ethanol precipitation and filtration, concentrating the supernatant into thick paste at 80 ℃, adding dextrin to prepare granules, spraying the volatile oil, and tabletting to obtain the third batch of gallbladder warming tablets.
Method for measuring synephrine transfer rate and hesperidin transfer rate of Wendan tablets
The synephrine standard and the hesperidin standard used for the determination are provided by China food and drug testing research institute, and the batch numbers are 110727-.
Method for measuring synephrine transfer rate of Wendan tablet
(1) Quality determination of synephrine in Wendan tablet
Firstly, extracting a sample by a gallbladder warming sheet:
taking 10 warm gallbladder tablets (about 0.25 g/tablet) per batch, crushing, grinding into fine powder, weighing 1g of the warm gallbladder tablet fine powder, adding 50-100mL of 50-100% (v/v) methanol, weighing, carrying out ultrasonic treatment for 10-60min, cooling to room temperature, weighing again, supplementing the lost weight with 50-100% (v/v) methanol, cooling, filtering, precisely taking 10mL of subsequent filtrate, evaporating to dryness, dissolving the residue with 10mL of water, loading the residue into a column by a dry method through polyamide (60-90 meshes, 2.5g, the inner diameter of the residue is 1 cm), eluting with 25mL of water, collecting the eluate, transferring to a 25mL volumetric flask, adding water to the scale, and shaking uniformly to obtain the product;
measurement of synephrine content of the sample:
detecting the sample by using high performance liquid chromatography (Shimadzu LC-20AT high performance liquid chromatograph; SPD-M20A ultraviolet detector; Labsolutions data processing software system), wherein the chromatographic conditions are as follows: sample introduction amount: 10 mu l of the mixture; a chromatographic column: normal phase silica gel bonded Diol-based chromatography column (YMC-Pack Diol-120-NP, 250 × 4.6mm, 5 μm, 12 nm); mobile phase: acetonitrile is used as a mobile phase A, a 5mmol/L ammonium acetate solution is used as a mobile phase B, and the volume ratio of the mobile phase A to the mobile phase B is 80: 20; the detection wavelength is 275nm, the flow rate is 1.0mL/min, and the theoretical plate number is not less than 14000.
③ the method for calculating the synephrine mass in the Wendan tablet:
adding water into synephrine standard substance to prepare 7 standard solutions of 7.44 mug/mL, 14.88 mug/mL, 29.76 mug/mL, 59.52 mug/mL, 89.28 mug/mL, 119.04 mug/mL and 148.8 mug/mL respectively, detecting the 7 standard solutions according to the method, performing linear regression by taking the concentration of the standard solutions as an abscissa and the chromatographic peak area as an ordinate to obtain a linear equation y of 5218.2x-1829.9 and R of 0.9999, substituting the chromatographic peak area of the sample into the linear equation to calculate the synephrine content of the sample, and calculating the synephrine mass in the WEN-DAN tablet according to the following formula.
The quality of synephrine (μ g) ═ the synephrine content in the wendan tablet (μ g/mL) x 25mL × dilution times × the quality of each batch of wendan tablet (g)/the quality of wendan tablet fine powder (g)
The dilution factor was equal to the initial methanol volume (mL)/10 mL.
(2) And (3) measuring the quality of synephrine in medicinal materials:
in the formula I, both the immature bitter orange and the dried orange peel contain synephrine, the synephrine content in the immature bitter orange in the formula is determined according to pages 230-231 of pharmacopoeia of the people's republic of China (2010 edition), and page number difference can be caused due to different printing batches.
II, measuring the content of synephrine in the tangerine peel with the prescription:
i. extracting a sample from dried orange peel:
precisely weighing 3 parts (used for calculating the average value) of the dried orange peel medium powder, wherein each part is about 1g, respectively placing the dried orange peel medium powder into 200mL conical bottles with stoppers, precisely adding 100mL of methanol, weighing, and ultrasonically treating for 1 h. Weighing, adding methanol to complement weight loss, shaking, and filtering with 0.22 μm microporous membrane.
A sample detection method:
the determination of synephrine quality in the Wendan tablet is carried out according to the second step.
The difference lies in that: column temperature: 35 ℃; mobile phase a was 5mM ammonium acetate solution, mobile phase B was acetonitrile, and mobile phase A, B volume percent change is shown in table 1.
TABLE 1
A method of calculation:
dissolving synephrine standard with chromatographic pure methanol to obtain standard solution with synephrine content of 0.036mg/ml, and measuring the standard solution according to the above method. Calculating by adopting an external standard method to obtain the synephrine content of the sample, and calculating according to the following formula to obtain the synephrine content in the tangerine peel of the prescription.
The content of synephrine (mug/g) in the tangerine peel of the prescription is sample synephrine (mug/mL) multiplied by 100 mL/tangerine peel medium powder mass (g)
III, calculating the quality of the synephrine in the medicinal materials according to the following formula.
The mass (mug) of synephrine in the medicinal materials is equal to the mass (g) of prescription immature bitter orange multiplied by the synephrine content (mug/g) in the prescription immature bitter orange, the mass (g) of prescription dried orange peel multiplied by the synephrine content (mug/g) in the prescription dried orange peel
(3) Calculating the synephrine transfer rate of the Wendan tablets:
the synephrine transfer rate of the Wendan tablets is calculated according to the following formula.
Synephrine transfer rate of 100% × synephrine mass (μ g) in fel tablet/synephrine mass (μ g) in medicinal material
Method for measuring hesperidin transfer rate of (II) wendan tablets
(1) Measuring the quality of hesperidin in the gallbladder warming tablet:
firstly, extracting a sample by a gallbladder warming sheet:
grinding fel Ursi in mortar, precisely weighing 0.5g, placing in conical flask with plug, precisely adding 50mL methanol, sealing, weighing, ultrasonic treating (power 250W, frequency 59kHz) for 30min, cooling, weighing again, supplementing the weight loss with methanol, shaking, filtering, and collecting the filtrate.
Measuring the content of hesperidin in the sample:
detecting a sample by using high performance liquid chromatography, wherein the chromatographic conditions are as follows: sample introduction amount: 10 mu l of the mixture; octadecylsilane chemically bonded silica is used as a filling agent; acetonitrile-0.1% phosphoric acid (volume ratio 20: 80) is used as a mobile phase; the detection wavelength is 285 nm; column temperature: 35 ℃; the theoretical plate number is not less than 15000 in terms of hesperidin peak.
③ the method for calculating the content of hesperidin in the gallbladder warming tablet:
taking a proper amount of hesperidin standard, dissolving with pure water to prepare a standard solution of 0.11mg/mL, detecting the standard solution according to the method, and calculating the hesperidin quality in the gallbladder warming tablet by adopting an external standard method and according to the following formula.
The quality of hesperidin in the warm gallbladder tablet is V sample multiplied by A sample multiplied by C standard multiplied by m batch/(A standard multiplied by m sample)
Wherein, the sample V is the total volume (mL) of the sample, the sample A is the peak area of the sample, the sample C is the concentration (mu g/mL) of the standard solution, the sample A is the peak area of the standard solution, the sample m is the sampling amount (g) of the warm-gallbladder tablets, and the batch m is the mass (g) of each warm-gallbladder tablet.
(2) The quality of hesperidin in the medicinal materials is determined:
the immature bitter orange and the tangerine peel in the formula contain hesperidin, the hesperidin content in the tangerine peel in the formula is determined according to pages 176-177 of pharmacopoeia of the people's republic of China (2010 version), and page number difference can be caused due to different printing batches.
II, measuring the content of hesperidin in the immature bitter orange with the prescription:
i. extracting a sample from immature bitter orange:
reference (i) · (2). ii. i) the sample is extracted from dried orange peel. Except that the immature bitter orange middle powder is used for replacing the dried orange peel middle powder.
A sample detection method:
the samples were examined by high performance liquid chromatography. The chromatographic conditions are as follows: sample introduction amount: 10 mu L of the solution; a chromatographic column: YMC-Pack, ODS-AM, 4.6 x 250mm,5 μm; a detector: an ultraviolet detector; detection wavelength: 283 nm; column temperature: 35 ℃; flow rate: 1.0 mL/min; mobile phase A: water, mobile phase B acetonitrile, and the volume ratio of A to B is 80: 20.
a method of calculation:
dissolving hesperidin standard with chromatographic pure methanol to obtain standard solution with hesperidin content of 0.080mg/mL, and detecting the standard solution according to the above method. And calculating to obtain the hesperidin content of the sample by adopting an external standard method, and calculating to obtain the hesperidin content in the immature bitter orange in the formula by referring to the step (I) - (2), the step (II) and the step (iii).
III, calculating the mass of the hesperidin in the medicinal materials according to the following formula.
The weight (μ g) of hesperidin in the medicinal materials is multiplied by the weight (g) of prescription immature bitter orange and the content (μ g/g) of hesperidin in prescription immature bitter orange, and the weight (g) of prescription dried orange peel is multiplied by the content (μ g/g) of hesperidin in prescription dried orange peel
(3) Calculating the hesperidin transfer rate of the swertia mileensis tablet:
the transfer rate of the hesperidin in the gallbladder warming tablet is calculated according to the following formula.
The hesperidin transfer rate is 100% multiplied by the hesperidin quality (mu g) in the fel warming tablet/the hesperidin quality (mu g) in the medicinal materials
Thirdly, evaluating the stability of the process
The respective rates of synephrine transfer and hesperidin transfer were measured in accordance with II for batches of the Wendan tablets I, II and III of preparation examples 1 to 3, and the results are shown in Table 2.
TABLE 2
As can be seen from Table 2, the synephrine transfer rate in the production of the warming gallbladder tablets is far greater than the hesperidin transfer rate, and the synephrine transfer rate is easier to measure accurately and is suitable for being used as an index for evaluating the process stability. Moreover, the synephrine transfer rate of the preparation examples 1-3 is more than or equal to 40.8%, which indicates that the preparation process of the fel warming tablets of the preparation examples 1-3 has high stability.
In addition, 10 batches of the warming gallbladder tablets prepared according to preparation examples 1 to 3 were prepared, and 10 batches produced according to preparation example 1 were named as warming gallbladder tablets I1-Ⅰ1010 batches produced according to preparation example 2 and named as Wendan tablets II1-Ⅱ1010 batches produced in preparation example 3 and named as Wendan tablets III1-Ⅲ10. The synephrine transfer rate of each batch of the gallbladder warming tablets is measured according to the second criterion, and the result shows that the gallbladder warming tablets I1-Ⅰ10The synephrine transfer rate is close to 50.68%; warming gallbladder tablet II1-Ⅱ10The synephrine transfer rate is close to 51.94%; warming gallbladder tablet III1-Ⅲ10The synephrine transfer rate was close to 50.21%. The synephrine transfer rate is more than or equal to 40.8 percent, and the preparation process of the gallbladder warming tablet is stable.
In addition, when measuring the synephrine mass in the Wendan tablet I, two mobile phases A and B with the volume ratio of 80:20 and 90:10 are respectively adopted for sample detection, and the obtained liquid chromatogram is respectively shown in figures 1 and 2.
As can be seen from comparison of FIG. 1 and FIG. 2, the volume ratio of mobile phase A to B is 80:20, and the peak time is earlier than that of the mobile phase A to B when the volume ratio is 90:10, so that the detection speed is faster, the separation degree is better, and the base line is more stable.
Fourth, research on methodology for detecting process stability of gallbladder warming tablet
(1) Precision:
the prepared synephrine standard solution with the concentration of 29.76 mu g/mL is measured according to the two (one) (1) and (II) method, sample introduction is repeated for 6 times, and RSD is calculated, and the result is 1.41%, which indicates that the precision of the instrument is good.
(2) Stability:
the sample is extracted from the Winterepha I according to the method in the second (first) to the method in the first (1), the sample is measured for 5 times, 10 mu l of the sample is injected into the high performance liquid chromatography at the time points of the beginning, 6h, 12h, 24h and 36h respectively, the synephrine chromatographic peak area is measured, the RSD of the chromatographic peak area is calculated for 5 times to be 1.85, and the result shows that the extracted sample is stable within 36 hours.
(3) Reproducibility:
6 parts of samples of the swertia mileensis I are prepared and measured according to the method in the second (first) to (1), and the RSD of the content of synephrine in the swertia mileensis is 1.92, which indicates that the method has good reproducibility.
(4) And (3) sample recovery rate:
crushing and grinding 10 pieces of fel warming tablets I (the measured synephrine content is 3.80mg/g) into fine powder, weighing 6 parts of fel warming tablets 0.5g, respectively adding synephrine standard substance of about 1.9mg into a bottle with a corkscrew, respectively measuring the synephrine content of the added standard substance by a two.
The sample adding recovery rate is (adding standard substance synephrine content-wendan tablet I synephrine content)/standard substance adding amount is multiplied by 100%
As a result, the average value of the sample recovery rate of synephrine is 97.6%, the RSD is 0.96%, and the sample recovery rate meets the requirement, which shows that the method has higher accuracy.
Although specific embodiments of the invention have been described in detail, those skilled in the art will appreciate. Various modifications and substitutions of those details may be made in light of the overall teachings of the disclosure, and such changes are intended to be within the scope of the present invention. The full scope of the invention is given by the appended claims and any equivalents thereof.
Claims (3)
1. A method for detecting the process stability of a warming gallbladder tablet comprises the steps of measuring the synephrine transfer rate of the warming gallbladder tablet according to the following formula;
synephrine transfer rate of 100% × synephrine mass in indomethacin tablet (μ g)/[ mass of immature bitter orange in prescription (g) × synephrine content in immature bitter orange in prescription (μ g/g) + mass of dried orange peel in prescription (g) × synephrine content in dried orange peel in prescription (μ g/g) ];
wherein,
the quality determination of synephrine in the warming gallbladder tablet comprises the steps of mixing the warming gallbladder tablet with methanol, and determining the content of synephrine in an extracting solution by high performance liquid chromatography; wherein, the detection conditions of the high performance liquid chromatography are as follows: the chromatographic column is a normal phase silica gel bonded diol-based chromatographic column; acetonitrile is used as a mobile phase A, and a 5mmol/L ammonium acetate solution is used as a mobile phase B; the volume ratio of the mobile phase A to the mobile phase B is 80: 20; the flow rate of the mobile phase is 0.6-1.2 mL/min; the detection wavelength is 275 nm; the theoretical plate number is more than or equal to 14000;
the method for measuring the content of synephrine in the tangerine peel comprises the steps of mixing the tangerine peel with methanol, and measuring the content of the synephrine in an extracting solution by high performance liquid chromatography; wherein, the detection conditions of the high performance liquid chromatography are as follows: the chromatographic column is a normal phase silica gel bonded diol-based chromatographic column; taking 5mM ammonium acetate solution as a mobile phase A and acetonitrile as a mobile phase B; the flow rate of the mobile phase is 0.6-1.2 mL/min; the detection wavelength is 275 nm; the theoretical plate number is more than or equal to 14000; the column temperature was 35 ℃; the volume percent changes of mobile phase a and mobile phase B are shown in the table below,
2. the method of claim 1, wherein the step of determining the amount of synephrine in the prescribed citrus peel is characterized by any one or more of the following (1) to (4),
(1) before mixing, crushing the dried orange peel into medium powder;
(2) adding 50-100mL of methanol into per gram of dried orange peel;
(3) mixing under ultrasound, and after ultrasonic treatment, complementing the loss weight loss with methanol;
(4) filtering the extractive solution with filter membrane having pore diameter of 0.22 μm.
3. The method according to claim 1, wherein the step of measuring the synephrine mass in a Wenchol tablet is characterized by any one or more of the following (1) to (5),
(1) before mixing, crushing the warm gall pieces;
(2) mixing under ultrasound, and after ultrasonic treatment, complementing the loss weight loss with methanol;
(3) the methanol concentration is 50-100% v/v;
(4) adding 50-100mL of methanol into each gram of gallbladder warming tablets;
(5) the extract was filtered and the filtrate was evaporated to dryness-the residue dissolved-and eluted through a polyamide column for purification.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011272363.2A CN112505172B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in gallbladder warming tablets |
| CN201510381434.5A CN106323794B (en) | 2015-07-01 | 2015-07-01 | Method for detecting process stability of gallbladder warming tablets |
| CN202011272381.0A CN112505173B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in dried orange peel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510381434.5A CN106323794B (en) | 2015-07-01 | 2015-07-01 | Method for detecting process stability of gallbladder warming tablets |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011272363.2A Division CN112505172B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in gallbladder warming tablets |
| CN202011272381.0A Division CN112505173B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in dried orange peel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106323794A CN106323794A (en) | 2017-01-11 |
| CN106323794B true CN106323794B (en) | 2021-03-30 |
Family
ID=57726940
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011272363.2A Active CN112505172B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in gallbladder warming tablets |
| CN202011272381.0A Active CN112505173B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in dried orange peel |
| CN201510381434.5A Active CN106323794B (en) | 2015-07-01 | 2015-07-01 | Method for detecting process stability of gallbladder warming tablets |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011272363.2A Active CN112505172B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in gallbladder warming tablets |
| CN202011272381.0A Active CN112505173B (en) | 2015-07-01 | 2015-07-01 | Method for measuring synephrine content in dried orange peel |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN112505172B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113237963A (en) * | 2021-03-25 | 2021-08-10 | 朗致集团双人药业有限公司 | Detection method and application of synephrine content in traditional Chinese medicine composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4325908B2 (en) * | 2002-10-18 | 2009-09-02 | 長瀬産業株式会社 | Lipolysis accelerator, skin external preparation and food and drink using the same |
| KR100821567B1 (en) * | 2006-11-01 | 2008-04-15 | 한국화학연구원 | Method for the preparation of optically active 2-sulfonyloxy-1-phenylethanol derivatives |
| CN101366849B (en) * | 2007-08-15 | 2012-07-25 | 北京康仁堂药业有限公司 | Detection and content determination method for traditional Chinese medicine citrus aurantium |
| CN102346177B (en) * | 2011-05-13 | 2013-11-27 | 湖南汉森制药股份有限公司 | Method for detecting Simotang preparation |
-
2015
- 2015-07-01 CN CN202011272363.2A patent/CN112505172B/en active Active
- 2015-07-01 CN CN202011272381.0A patent/CN112505173B/en active Active
- 2015-07-01 CN CN201510381434.5A patent/CN106323794B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 便塞通颗粒的制备工艺及质量标准研究;张丹;《中国优秀硕士学位论文全文数据库 工程科技I辑》;20090715(第7期);第B016-47页 * |
| 关于《中国药典》2010年版枳实中辛弗林含量测定方法的商榷;刘海涛 等;《中国药品标准》;20131231;第14卷(第4期);前言，第1-3节 * |
| 廖茂梁 等.正交试验优选枳实中辛弗林提取工艺.《中国实验方剂学杂志》.2011,第17卷(第13期), * |
| 正交试验优选枳实中辛弗林提取工艺;廖茂梁 等;《中国实验方剂学杂志》;20110731;第17卷(第13期);前言，第1-3节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112505173B (en) | 2023-02-03 |
| CN112505172A (en) | 2021-03-16 |
| CN112505173A (en) | 2021-03-16 |
| CN112505172B (en) | 2023-02-03 |
| CN106323794A (en) | 2017-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101278991B (en) | Method for testing effective ingredients of Gegen Qinlian medicine | |
| CN106290599B (en) | Content determination method of traditional Chinese medicine composition | |
| CN104391072A (en) | Quality control method of traditional Chinese medicine compound preparation for treating osteoporosis | |
| CN102058814B (en) | General flavone extractive of four medicaments including grassleaf sweetflag rhizome and preparation method thereof | |
| CN110579545A (en) | Quality detection method of traditional Chinese medicine composition for clearing heat and ventilating lung | |
| CN101926889A (en) | Method for detecting white paeony root-medlar particles | |
| CN106323794B (en) | Method for detecting process stability of gallbladder warming tablets | |
| CN114942291B (en) | Quality detection method of yang-suppressing yin-nourishing particles | |
| WO2009155756A1 (en) | Method for determining the contents of oligosaccharides in morinda officinalis chinese medicine or extraction thereof | |
| CN101797360A (en) | Fingerprint detection method for analgesic plaster | |
| CN112881540A (en) | Method for detecting bupleurum chinense and vinegar bupleurum chinense formula granules | |
| CN116242933A (en) | Method for measuring content of 8 ingredients in Xiongju Shangqing tablet | |
| CN107976498B (en) | Method for detecting functional effective components of caulis spatholobi and application | |
| CN107764924B (en) | Detection method of effective components in asthma granules | |
| CN1877322B (en) | High-efficiency liquid chromatography method for detecting stachydrine content in motherwort | |
| CN113759057B (en) | Characteristic spectrum of allium macrostemon white water extract and preparation thereof and construction method thereof | |
| CN113759056B (en) | Characteristic spectrum of Chinese lobelia and preparation thereof and construction method thereof | |
| CN102008541B (en) | Method for simultaneously detecting three main active ingredients in sugar-free type compound wintercreeper preparation | |
| CN110967415B (en) | Method for measuring verbascoside in serum-nourishing brain water extract | |
| CN114403328A (en) | An anti-hangover beverage prepared from semen Hoveniae and radix Puerariae | |
| CN107894466B (en) | Determination method of HPLC fingerprint of Jinsangqi antitoxic preparation and quality control method of Jinsangqi antitoxic preparation | |
| CN114646695B (en) | Ultra-high performance liquid chromatography detection method of starwort root standard decoction and application thereof | |
| CN114720614B (en) | Method for detecting content of asiaticoside-B and/or madecassoside by HPLC-CAD method | |
| CN113533563B (en) | Method for simultaneously detecting contents of four components of liver-soothing, stomach-harmonizing and pain-relieving traditional Chinese medicine | |
| CN114965739B (en) | Method for detecting kadsura pepper stem and preparation and quality control method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210810 Address after: 363000 1 Street, Zhangzhou, Fujian Patentee after: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Address before: Compound No.16, Airport Road, Baiyun District, Guangzhou City, Guangdong Province Patentee before: The First Affiliated Hospital of Guangzhou University of traditional Chinese Medicine |
|
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 363000 No. 1, Amber Road, Xiangcheng District, Zhangzhou City, Fujian Province Patentee after: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. Address before: 363000 1 Street, Zhangzhou, Fujian Patentee before: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL Co.,Ltd. |